Patricia A. Cane
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Patricia A. Cane has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Graham Francis Medley
Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom; Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom
3 shared publications D. James Nokes
Kenya Medical Research Institute, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya,1 Health Protection Agency, Centre for Infections, Colindale, London, United Kingdom,2 Department of Biological Sciences, University of Warwick, Coventry, United Kingdom3
2 shared publications- Emelda A. Okiro
Population and Health Impact Surveillance Group, Kenya Medical Research Institute-Wellcome Trust Research Programme, Nairobi, Kenya
2 shared publications - A. Sarah Walker
MRC Clinical Trials Unit, London, UK
1 shared publication Amin S. Hassan
Kenya Medical Research Institute, Centre for Geographic Medicine Research–Coast, Kilifi, Kenya
1 shared publicationAnn Bett
Kenya Medical Research Institute, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya,1 Health Protection Agency, Centre for Infections, Colindale, London, United Kingdom,2 Department of Biological Sciences, University of Warwick, Coventry, United Kingdom3
1 shared publication
Latest Publications
- 1 February 2012
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 28 (2) , 220-224
HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination
The extent of HIV-1 diversity was examined among patients attending a rural district hospital in a coastal area of Kenya. The pol gene was sequenced in samples from 153 patients. Subtypes were designated using the REGA, SCUEAL, and jpHMM programs. The most common subtype was A1, followed by C and D; A2 and G were also detected. However, a large proportion of the samples was found to be recombinants, which clustered within the pure subtype branches. Phylogeographic analysis of Kilifi sequences compared with those from other regions of Africa showed that while many sequences were closely related to sequences from Kenya, others were most closely related to known sequences from other parts of Africa, including West Africa. Overall, these data indicate that there have been multiple introductions of HIV-1 into this small rural town and surroundings with ongoing diversity being generated by recombination.
- 1 February 2012
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 28 (2) , 220-224
HIV Type 1 in a Rural Coastal Town in Kenya Shows Multiple Introductions with Many Subtypes and Much Recombination
The extent of HIV-1 diversity was examined among patients attending a rural district hospital in a coastal area of Kenya. The pol gene was sequenced in samples from 153 patients. Subtypes were designated using the REGA, SCUEAL, and jpHMM programs. The most common subtype was A1, followed by C and D; A2 and G were also detected. However, a large proportion of the samples was found to be recombinants, which clustered within the pure subtype branches. Phylogeographic analysis of Kilifi sequences compared with those from other regions of Africa showed that while many sequences were closely related to sequences from Kenya, others were most closely related to known sequences from other parts of Africa, including West Africa. Overall, these data indicate that there have been multiple introductions of HIV-1 into this small rural town and surroundings with ongoing diversity being generated by recombination.
- Open Access
- 11 May 2011
- Published by Springer Nature in Retrovirology
- Vol. 8 (1) , 31
The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains
The Q151M multi-drug resistance (MDR) pathway in HIV-1 reverse transcriptase (RT) confers reduced susceptibility to all nucleoside reverse transcriptase inhibitors (NRTIs) excluding tenofovir (TDF). This pathway emerges after long term failure of therapy, and is increasingly observed in the resource poor world, where antiretroviral therapy is rarely accompanied by intensive virological monitoring. In this study we examined the genotypic, phenotypic and fitness correlates associated with the development of Q151M MDR in the absence of viral load monitoring.
- 11 May 2011
- Published by Springer Nature in Retrovirology
- Vol. 8 (1) , 31
Open AccessThe evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains
The Q151M multi-drug resistance (MDR) pathway in HIV-1 reverse transcriptase (RT) confers reduced susceptibility to all nucleoside reverse transcriptase inhibitors (NRTIs) excluding tenofovir (TDF). This pathway emerges after long term failure of therapy, and is increasingly observed in the resource poor world, where antiretroviral therapy is rarely accompanied by intensive virological monitoring. In this study we examined the genotypic, phenotypic and fitness correlates associated with the development of Q151M MDR in the absence of viral load monitoring.
- 1 October 2010
- Published by American Society for Microbiology in Journal of Virology
- Vol. 84 (19) , 10425-10428
Intrapatient Variation of the Respiratory Syncytial Virus Attachment Protein Gene
Intrapatient variability of the attachment (G) protein gene of respiratory syncytial virus (RSV) was examined using both population and single-genome sequencing. Samples from three patients infected with a group B virus variant which has a 60-nucleotide duplication in the G protein gene were examined. These samples were chosen because occasional mixed sequence bases were observed. In a minority of RSV genomes from these patients considerable variability was found, including point mutations, insertions, and deletions. Of particular note, the deletion of the exact portion of the gene which had been duplicated in some isolates was observed in viral RNAs from two patients.
- 1 October 2010
- Published by American Society for Microbiology in Journal of Virology
- Vol. 84 (19) , 10425-10428
Intrapatient Variation of the Respiratory Syncytial Virus Attachment Protein Gene
Intrapatient variability of the attachment (G) protein gene of respiratory syncytial virus (RSV) was examined using both population and single-genome sequencing. Samples from three patients infected with a group B virus variant which has a 60-nucleotide duplication in the G protein gene were examined. These samples were chosen because occasional mixed sequence bases were observed. In a minority of RSV genomes from these patients considerable variability was found, including point mutations, insertions, and deletions. Of particular note, the deletion of the exact portion of the gene which had been duplicated in some isolates was observed in viral RNAs from two patients.
- 16 August 2010
- Published by Springer Nature
- Vol. 665, 123-132
HIV Drug Resistance Testing
HIV genotypic resistance testing has become a routine test informing the management of HIV-positive patients. This chapter describes the background of this testing and provides a protocol for undertaking the assay by a home-brew method. Methods for interpretation of the data are also outlined.
- 16 August 2010
- Published by Springer Nature
- Vol. 665, 123-132
HIV Drug Resistance Testing
HIV genotypic resistance testing has become a routine test informing the management of HIV-positive patients. This chapter describes the background of this testing and provides a protocol for undertaking the assay by a home-brew method. Methods for interpretation of the data are also outlined.
- Open Access
- 22 January 2010
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 10 (1) , 15
Duration of shedding of respiratory syncytial virus in a community study of Kenyan children
Our understanding of the transmission dynamics of respiratory syncytial virus (RSV) infection will be better informed with improved data on the patterns of shedding in cases not limited only to hospital admissions.
- 22 January 2010
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 10 (1) , 15
Open AccessDuration of shedding of respiratory syncytial virus in a community study of Kenyan children
Our understanding of the transmission dynamics of respiratory syncytial virus (RSV) infection will be better informed with improved data on the patterns of shedding in cases not limited only to hospital admissions.
- Open Access
- 12 August 2009
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 64 (Supplement) , i37-i40
New developments in HIV drug resistance
Several new antiretroviral drugs have recently been licensed for use in HIV-1-infected patients. These include drugs in two new classes: an integrase inhibitor (raltegravir) and a CCR5 co-receptor antagonist (maraviroc). In addition, two new protease inhibitors, atazanavir and darunavir, which have activity against viruses resistant to other protease inhibitors, have come into clinical use. Finally etravirine, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) is being increasingly used in patients whose virus is resistant to the earlier NNRTIs. These clinical advances have required the development of novel assays and interpretation systems for detection of resistance to allow the laboratory monitoring of patients receiving these new therapies.
- 12 August 2009
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 64 (Supplement) , i37-i40
Open AccessNew developments in HIV drug resistance
Several new antiretroviral drugs have recently been licensed for use in HIV-1-infected patients. These include drugs in two new classes: an integrase inhibitor (raltegravir) and a CCR5 co-receptor antagonist (maraviroc). In addition, two new protease inhibitors, atazanavir and darunavir, which have activity against viruses resistant to other protease inhibitors, have come into clinical use. Finally etravirine, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) is being increasingly used in patients whose virus is resistant to the earlier NNRTIs. These clinical advances have required the development of novel assays and interpretation systems for detection of resistance to allow the laboratory monitoring of patients receiving these new therapies.
- 1 December 2007
- Vol. 12 (4) , 82-4
Epidemiology of antiretroviral resistance and impact on treatment outcomes.
- 1 December 2007
- Vol. 12 (4) , 82-4
Epidemiology of antiretroviral resistance and impact on treatment outcomes.
- 12 October 2007
- Published by Wiley in Journal of Medical Virology
- Vol. 79 (12) , 1943-1950
Comparison of strain‐specific antibody responses during primary and secondary infections with respiratory syncytial virus
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection in infants. RSV repeatedly reinfects individuals: this may be due in part to the variability of the attachment (G) glycoprotein and changes in this protein have been shown to be under positive selection. Infants experiencing their primary infection show a genotype‐specific antibody response with respect to the variable regions of the G protein. A prospective study of RSV infections in a birth cohort in rural Kenya identified infants experiencing repeat infections with RSV. The serum antibody responses of these infants were investigated with respect to their anti‐RSV reactions in an enzyme‐linked immunosorbent assay (ELISA) and the specificity of the response to a variable region of the G protein by ELISA and immunoblotting using bacterially expressed polypeptides representative of the currently circulating strains of RSV. The results presented here confirm that the primary antibody response to the variable regions of the G protein is generally genotype‐specific, but show that the response may become cross‐reactive (at least within group A viruses) during secondary infections even where the secondary infection is of the same genotype as the initial infection. Also, some infants who did not mount a detectable antibody response to whole RSV antigens during their primary infection nevertheless showed genotype‐specific responses to the G protein. In conclusion, the strain‐specific nature of the serum antibody response to the variable regions of the G protein of RSV observed in primary infections can become cross‐reactive in subsequent reinfections. J. Med. Virol. 79:1943–1950, 2007.
- 12 October 2007
- Published by Wiley in Journal of Medical Virology
- Vol. 79 (12) , 1943-1950
Comparison of strain‐specific antibody responses during primary and secondary infections with respiratory syncytial virus
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection in infants. RSV repeatedly reinfects individuals: this may be due in part to the variability of the attachment (G) glycoprotein and changes in this protein have been shown to be under positive selection. Infants experiencing their primary infection show a genotype‐specific antibody response with respect to the variable regions of the G protein. A prospective study of RSV infections in a birth cohort in rural Kenya identified infants experiencing repeat infections with RSV. The serum antibody responses of these infants were investigated with respect to their anti‐RSV reactions in an enzyme‐linked immunosorbent assay (ELISA) and the specificity of the response to a variable region of the G protein by ELISA and immunoblotting using bacterially expressed polypeptides representative of the currently circulating strains of RSV. The results presented here confirm that the primary antibody response to the variable regions of the G protein is generally genotype‐specific, but show that the response may become cross‐reactive (at least within group A viruses) during secondary infections even where the secondary infection is of the same genotype as the initial infection. Also, some infants who did not mount a detectable antibody response to whole RSV antigens during their primary infection nevertheless showed genotype‐specific responses to the G protein. In conclusion, the strain‐specific nature of the serum antibody response to the variable regions of the G protein of RSV observed in primary infections can become cross‐reactive in subsequent reinfections. J. Med. Virol. 79:1943–1950, 2007.
- 19 February 2007
- Published by Wolters Kluwer Health in AIDS
- Vol. 21 (4) , 447-455
Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase
To identify accessory mutations associated with high levels of resistance to reverse transcriptase inhibitors (RTI). HIV pol sequences from routine resistance tests from over 3000 patients who were treatment experienced and infected with subtype B HIV-1 were analysed. Changes relative to the wild-type amino acid for codons 1–400 of reverse transcriptase were determined in two series: (i) samples showing the accumulation of thymidine analogue mutations (TAMs); and (ii) samples showing the accumulation of non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations. Accessory mutations were identified as occurring in those codons in which there was a statistically significant association between the distribution of amino acids and the number of TAMs/NNRTI resistance mutations. Positions already established as drug resistance positions by the International AIDS Society – USA Panel were not included in this analysis. Twenty-four positions were identified where accessory mutations were associated with the accumulation of TAMs (20, 35, 39, 43, 60, 83, 98, 101, 122, 135, 179, 196, 203, 208, 218, 223, 228, 284, 322, 356, 359, 360, 371 and 381). Likewise changes at 25 positions (6, 20, 35, 39, 43, 53, 68, 90, 98, 101, 122, 179, 200, 203, 208, 218, 221, 223, 228, 284, 318, 320, 348, 359 and 371) were associated with NNRTI mutations. The accumulation of accessory mutations correlated with increasing numbers of TAMs and NNRTI mutations. The development of high-level resistance to RTI is associated not only with the accumulation of recognized mutations but also with accessory mutations.
- 19 February 2007
- Published by Wolters Kluwer Health in AIDS
- Vol. 21 (4) , 447-455
Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase
To identify accessory mutations associated with high levels of resistance to reverse transcriptase inhibitors (RTI). HIV pol sequences from routine resistance tests from over 3000 patients who were treatment experienced and infected with subtype B HIV-1 were analysed. Changes relative to the wild-type amino acid for codons 1–400 of reverse transcriptase were determined in two series: (i) samples showing the accumulation of thymidine analogue mutations (TAMs); and (ii) samples showing the accumulation of non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations. Accessory mutations were identified as occurring in those codons in which there was a statistically significant association between the distribution of amino acids and the number of TAMs/NNRTI resistance mutations. Positions already established as drug resistance positions by the International AIDS Society – USA Panel were not included in this analysis. Twenty-four positions were identified where accessory mutations were associated with the accumulation of TAMs (20, 35, 39, 43, 60, 83, 98, 101, 122, 135, 179, 196, 203, 208, 218, 223, 228, 284, 322, 356, 359, 360, 371 and 381). Likewise changes at 25 positions (6, 20, 35, 39, 43, 53, 68, 90, 98, 101, 122, 179, 200, 203, 208, 218, 221, 223, 228, 284, 318, 320, 348, 359 and 371) were associated with NNRTI mutations. The accumulation of accessory mutations correlated with increasing numbers of TAMs and NNRTI mutations. The development of high-level resistance to RTI is associated not only with the accumulation of recognized mutations but also with accessory mutations.
- 1 December 2005
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 18 (6) , 537-542
Stability of transmitted drug-resistant HIV-1 species
The proportion of patients showing primary infection with HIV-1 that are already resistant to antiviral drugs has been steadily increasing. Such resistance is known to compromise therapy response. Most patients, however, are not diagnosed during their incident infection and, until recently, it was not known for how long resistant virus can be detected following infection. This article reviews reports on the stability of transmitted resistance in the absence of therapy. It has now been shown that many resistance-associated mutations can persist for a considerable time following transmission in the absence of treatment and that such resistance can be further transmitted. Since transmitted resistance can be detected years after infection, it is now worthwhile carrying out resistance tests on newly diagnosed patients in which it is known that the level of transmitted resistance in the population warrants such testing.
- 1 December 2005
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 18 (6) , 537-542
Stability of transmitted drug-resistant HIV-1 species
The proportion of patients showing primary infection with HIV-1 that are already resistant to antiviral drugs has been steadily increasing. Such resistance is known to compromise therapy response. Most patients, however, are not diagnosed during their incident infection and, until recently, it was not known for how long resistant virus can be detected following infection. This article reviews reports on the stability of transmitted resistance in the absence of therapy. It has now been shown that many resistance-associated mutations can persist for a considerable time following transmission in the absence of treatment and that such resistance can be further transmitted. Since transmitted resistance can be detected years after infection, it is now worthwhile carrying out resistance tests on newly diagnosed patients in which it is known that the level of transmitted resistance in the population warrants such testing.